Description
Product Specifications
- Product: Selank 30mg
- Compound / formulation: Selank (tuftsin-derived synthetic peptide)
- Labeled quantity / volume: 30mg per vial
- Physical form: White lyophilized powder
- Research focus: Anxiety-Related Research; Stress-Response Research; Neurobehavioral Signaling; Peptide Signaling
- Available batch identifiers: Blue (reported batch designation)
- SKU: HOP-SELANK-30MG
- Intended classification: Laboratory research only
The labeled quantity is 30mg. The independent report below describes the submitted blue-cap sample; it does not establish the measured contents of every vial.
Independent Laboratory Testing
Blue cap — Janoshik Analytical, report #165288
- Compound reported: Selank 30mg
- Measured content: 30.08mg
- Purity: 99.544%
- Test date: May 28, 2026
- View laboratory report
House of Peptides maintains an established testing and sampling protocol with its suppliers. Under this agreed protocol, samples are randomly selected from a production batch and submitted for independent laboratory analysis.
The submitted samples are drawn from the same production batch as the corresponding inventory supplied to House of Peptides. This batch-based sampling approach provides analytical information associated with the production batch rather than individual testing of every vial.
House of Peptides may maintain inventory from multiple production batches of the same compound. Each Certificate of Analysis corresponds to its identified batch, which may be distinguished by cap color or lot designation. Orders are fulfilled on a first-in, first-out (FIFO) basis, so the batch supplied depends on available inventory at the time of fulfillment. Laboratory findings apply to the submitted samples from their respective batches, not to every individual vial.
Scientific Research Background
Feeling anxious is part of the body's normal response to uncertainty or perceived danger. Scientists study this response by looking at how the brain processes signals, how people describe their symptoms, and how those symptoms change during controlled research.
Selank is a synthetic peptide made from seven amino acids. Its first four amino acids match a naturally occurring fragment called tuftsin; three additional amino acids extend that sequence. Researchers have studied Selank as a distinct compound rather than assuming it behaves exactly like tuftsin.
Some published human studies examined Selank in people experiencing anxiety-related disorders. Researchers compared measurements of anxiety and related symptoms with those observed in groups receiving established medicines. Other investigations have explored biological signals associated with anxiety, including the breakdown of naturally occurring signaling peptides.
Most of the cited clinical publications are relatively small, were published in Russian, and provide limited methodological detail in their English abstracts. Results from these studies should not be mistaken for proof that Selank is an established treatment or that any commercial research vial is equivalent to the materials studied.
Compound details
- Amino-acid sequence: Thr–Lys–Pro–Arg–Pro–Gly–Pro (TKPRPGP)
- Peptide length: Seven amino acids
- Research classification: Peptide
Clinical Research Observations
1. Why are researchers interested in Selank and anxiety?
Anxiety can affect thoughts, sleep, concentration, and how the body responds to everyday situations. Researchers use questionnaires and clinical assessments to measure these experiences more consistently.
What researchers found: Investigators have studied Selank in small groups of people with anxiety-related conditions, looking for changes in reported symptoms and clinical ratings. Some studies reported improvements during the observation period.
Why it matters: These findings explain why Selank attracted research interest. They do not establish that it reliably reduces anxiety in the wider population or that a laboratory research product has a clinical use.
2. What happened when Selank was compared with an established anxiety medicine?
Comparing an experimental substance with an existing medicine can help researchers understand how participants respond. But a comparison with an active medicine does not answer every question that a placebo-controlled trial could address.
What researchers found: A 2008 study examined 62 people with generalized anxiety disorder or neurasthenia. Thirty received Selank and 32 received medazepam. The investigators reported similar improvements in certain anxiety ratings and additional changes in fatigue-related symptoms in the Selank group.
Why it matters: The study provides human research observations, but its size and comparison design limit what can be concluded. It does not prove that Selank is equally effective or safe across broader patient populations.
3. Did another study compare Selank with a different medicine?
Scientists often repeat a research question using different groups and comparison treatments to see whether findings are consistent.
What researchers found: A 2014 clinical study involving 60 people with anxiety-related conditions compared Selank with phenazepam. The researchers reported improvements in anxiety ratings and some measures of daily functioning during the study.
Why it matters: This adds to the published human evidence, but it does not replace large, independently replicated trials. The findings cannot be used to promise anxiety relief from this product.
4. What did researchers learn when Selank was studied alongside another medicine?
Some studies investigate combinations rather than a substance on its own. Those results need careful interpretation because both treatments may influence the outcome.
What researchers found: In a 2015 study, investigators compared 30 patients receiving phenazepam alone with 40 receiving phenazepam together with Selank. The combination group showed changes in several clinical measures, according to the published abstract.
Why it matters: A combination study cannot establish what Selank would do on its own. It also cannot determine whether those results would occur in people outside the study.
5. Why did researchers measure a substance in the blood?
The body makes small molecules that help cells communicate. Some of these molecules are broken down quickly, and scientists sometimes measure that process while studying stress-related conditions.
What researchers found: The 2008 investigation also measured the breakdown of leu-enkephalin, a naturally occurring signaling peptide, in blood samples. The researchers reported differences associated with the participants' symptoms and changes during the study.
Why it matters: Blood measurements may help researchers explore possible biological explanations. They do not establish that changing one laboratory measurement causes an improvement in anxiety or other symptoms.
6. Does Selank's connection to tuftsin tell us how it works?
A peptide's structure can provide clues about why scientists choose to study it. But related molecules do not necessarily have identical effects.
What researchers found: Selank contains the four-amino-acid tuftsin sequence with three additional amino acids. Laboratory studies examine possible pathways involved in its experimental activity, but a single, clinically proven explanation has not been established.
Why it matters: Knowing the structure helps identify the molecule being researched. It does not by itself establish a benefit, an appropriate application, or a safety profile.
7. What can we conclude from the available research?
Small clinical studies can identify findings worth exploring. Stronger conclusions usually require larger trials with transparent methods, suitable comparisons, and results reproduced by independent researchers.
What researchers found: Published studies have reported changes in anxiety-related ratings and biological measurements. However, the available evidence remains limited by study size, design, reporting detail, and independent replication.
Why it matters: Selank remains an area of scientific investigation. The cited research does not establish that House of Peptides' Selank 30mg treats anxiety, improves cognitive performance, or is safe for human administration.
Published Scientific Research
The following studies concern Selank research preparations and do not establish the clinical properties of House of Peptides' Selank 30mg.
Zozulia et al. (2008) — Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova. A study of 62 participants comparing Selank with medazepam; also investigated blood leu-enkephalin measures. PubMed — PMID 18454096. Supports: Questions 1, 2 and 5.
Medvedev et al. (2014) — A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders. Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova. A comparison involving 60 participants. PubMed — PMID 25176261. Supports: Question 3.
Optimization of the treatment of anxiety disorders with selank (2015). Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova. Compared phenazepam alone with phenazepam plus Selank in 70 participants. PubMed — PMID 26356395. DOI:
10.17116/jnevro20151156133-40. Supports: Question 4.Vyunova et al. (2018) — Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein & Peptide Letters. Laboratory investigation of Selank-associated modulation of GABA receptor binding. PubMed — PMID 30255741. DOI:
10.2174/0929866525666180925144642. Supports: Questions 6 and 7.
Evidence boundary: These publications do not establish the safety, efficacy, or equivalence of this research inventory. The human studies have important limitations, including small samples and incomplete methodological information available in English abstracts.
Understanding the Research Findings
Selank is a seven-amino-acid peptide studied in connection with anxiety-related behavior and communication between cells.
Several small human studies reported changes in anxiety measurements, including studies comparing Selank with established medicines. Other research has examined possible biological explanations for those observations.
The available studies do not establish that Selank reliably treats anxiety, improves concentration, or provides a clinically meaningful benefit in the general population. Their findings also cannot establish the safety or effectiveness of this particular research product.
The independent Janoshik report documents analytical results for the identified blue-cap sample.
Research Use Notice
For laboratory research only. Not intended for human or veterinary administration, diagnostic, or therapeutic use.
Reviews
There are no reviews yet.